Overview Dividends

(ECL) Ecolab - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2788651006

Water Treatment, Hygiene Products, Infection Prevention, Pest Control

ECL EPS (Earnings per Share)

EPS (Earnings per Share) of ECL over the last years for every Quarter: "2020-09-30": 1.15, "2020-12-31": 1.23, "2021-03-31": 0.91, "2021-06-30": 1.22, "2021-09-30": 1.41, "2021-12-31": 1.28, "2022-03-31": 0.82, "2022-06-30": 1.1, "2022-09-30": 1.3, "2022-12-31": 1.27, "2023-03-31": 0.88, "2023-06-30": 1.24, "2023-09-30": 1.54, "2023-12-31": 1.55, "2024-03-31": 1.34, "2024-06-30": 1.68, "2024-09-30": 1.83, "2024-12-31": 1.81, "2025-03-31": 1.5, "2025-06-30": 1.89, "2025-09-30": 0,
EPS Growth (3Y CAGR): -55.65%
EPS Trend (3Y Correlation): -12.8%

ECL Revenue

Revenue of ECL over the last years for every Quarter: 2020-09-30: 3018.6, 2020-12-31: 3065.3, 2021-03-31: 2885, 2021-06-30: 3162.7, 2021-09-30: 3320.8, 2021-12-31: 3364.6, 2022-03-31: 3266.7, 2022-06-30: 3580.6, 2022-09-30: 3669.3, 2022-12-31: 3671.2, 2023-03-31: 3571.6, 2023-06-30: 3852.1, 2023-09-30: 3958.1, 2023-12-31: 3938.4, 2024-03-31: 3751.9, 2024-06-30: 3985.8, 2024-09-30: 3998.5, 2024-12-31: 4005.2, 2025-03-31: 3695, 2025-06-30: 4025.2, 2025-09-30: null,
Revenue Growth (3Y CAGR): 3.75%
Revenue Trend (3Y Correlation): 53.4%

Description: ECL Ecolab

Ecolab Inc. (NYSE:ECL) delivers water, hygiene, and infection-prevention solutions worldwide through four reportable segments: Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Global Pest Elimination. The company’s product portfolio spans water-treatment chemicals, cleaning and sanitizing agents, and pest-control services, sold via field sales teams, corporate accounts, distributors, and dealers.

In FY 2023 Ecolab generated roughly $13.5 billion in revenue, with an adjusted operating margin of about 14 % and a free-cash-flow conversion rate near 70 %. The Global Industrial segment remains the largest revenue driver, benefiting from rising demand for water-recycling technologies in energy-intensive industries, while the Healthcare & Life Sciences segment is gaining traction as hospitals and pharma firms increase spending on infection-control protocols post-COVID-19.

Key macro-economic levers include global industrial production growth (especially in emerging markets), tightening environmental regulations that spur water-conservation investments, and inflationary pressure on raw-material costs, which can compress margins if not offset by pricing power. Ecolab’s historical ability to pass through cost increases and its focus on recurring service contracts provide a partial hedge against these risks.

For a deeper, data-driven look at Ecolab’s valuation scenarios and sensitivity analyses, the resources available on ValueRay may prove helpful.

ECL Stock Overview

Market Cap in USD 75,390m
Sub-Industry Specialty Chemicals
IPO / Inception 1988-01-05

ECL Stock Ratings

Growth Rating 74.5%
Fundamental 69.7%
Dividend Rating 53.9%
Return 12m vs S&P 500 -9.70%
Analyst Rating 3.73 of 5

ECL Dividends

Dividend Yield 12m 0.99%
Yield on Cost 5y 1.38%
Annual Growth 5y 4.54%
Payout Consistency 96.7%
Payout Ratio 37.0%

ECL Growth Ratios

Growth Correlation 3m 18.8%
Growth Correlation 12m 71.5%
Growth Correlation 5y 51.9%
CAGR 5y 22.82%
CAGR/Max DD 3y (Calmar Ratio) 1.32
CAGR/Mean DD 3y (Pain Ratio) 6.32
Sharpe Ratio 12m 1.28
Alpha 0.00
Beta 0.937
Volatility 17.32%
Current Volume 1392.4k
Average Volume 20d 1428.9k
Stop Loss 261.6 (-3%)
Signal -0.67

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (2.14b TTM) > 0 and > 6% of Revenue (6% = 943.4m TTM)
FCFTA 0.07 (>2.0%) and ΔFCFTA -3.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 13.78% (prev 12.18%; Δ 1.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 2.62b > Net Income 2.14b (YES >=105%, WARN >=100%)
Net Debt (7.05b) to EBITDA (3.95b) ratio: 1.78 <= 3.0 (WARN <= 3.5)
Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (285.4m) change vs 12m ago -0.56% (target <= -2.0% for YES)
Gross Margin 43.97% (prev 42.60%; Δ 1.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 69.58% (prev 72.85%; Δ -3.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 9.60 (EBITDA TTM 3.95b / Interest Expense TTM 312.9m) >= 6 (WARN >= 3)

Altman Z'' 3.91

(A) 0.09 = (Total Current Assets 7.08b - Total Current Liabilities 4.91b) / Total Assets 23.74b
(B) 0.51 = Retained Earnings (Balance) 12.08b / Total Assets 23.74b
(C) 0.13 = EBIT TTM 3.00b / Avg Total Assets 22.60b
(D) 0.73 = Book Value of Equity 10.44b / Total Liabilities 14.39b
Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 69.69

1. Piotroski 6.0pt = 1.0
2. FCF Yield 1.92% = 0.96
3. FCF Margin 10.01% = 2.50
4. Debt/Equity 0.90 = 2.11
5. Debt/Ebitda 2.12 = -0.23
6. ROIC - WACC (= 6.38)% = 7.98
7. RoE 23.99% = 2.00
8. Rev. Trend 53.45% = 4.01
9. EPS Trend -12.83% = -0.64

What is the price of ECL shares?

As of October 02, 2025, the stock is trading at USD 269.71 with a total of 1,392,374 shares traded.
Over the past week, the price has changed by +1.01%, over one month by -1.61%, over three months by -0.83% and over the past year by +7.45%.

Is Ecolab a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Ecolab (NYSE:ECL) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 69.69 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECL is around 269.48 USD . This means that ECL is currently overvalued and has a potential downside of -0.09%.

Is ECL a buy, sell or hold?

Ecolab has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold ECL.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 13
  • Sell: 1
  • Strong Sell: 0

What are the forecasts/targets for the ECL price?

Issuer Target Up/Down from current
Wallstreet Target Price 286.6 6.3%
Analysts Target Price 286.6 6.3%
ValueRay Target Price 300.7 11.5%

Last update: 2025-09-25 04:03

ECL Fundamental Data Overview

Market Cap USD = 75.39b (75.39b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 1.92b USD (last quarter)
P/E Trailing = 35.5361
P/E Forward = 31.25
P/S = 4.7946
P/B = 8.0888
P/EG = 2.8427
Beta = 1.08
Revenue TTM = 15.72b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.95b USD
Long Term Debt = 7.52b USD (from longTermDebt, last quarter)
Short Term Debt = 844.6m USD (from shortTermDebt, last quarter)
Debt = 8.37b USD (Calculated: Short Term 844.6m + Long Term 7.52b)
Net Debt = 7.05b USD (from netDebt column, last quarter)
Enterprise Value = 81.84b USD (75.39b + Debt 8.37b - CCE 1.92b)
Interest Coverage Ratio = 9.60 (Ebit TTM 3.00b / Interest Expense TTM 312.9m)
FCF Yield = 1.92% (FCF TTM 1.57b / Enterprise Value 81.84b)
FCF Margin = 10.01% (FCF TTM 1.57b / Revenue TTM 15.72b)
Net Margin = 13.59% (Net Income TTM 2.14b / Revenue TTM 15.72b)
Gross Margin = 43.97% ((Revenue TTM 15.72b - Cost of Revenue TTM 8.81b) / Revenue TTM)
Tobins Q-Ratio = 7.84 (Enterprise Value 81.84b / Book Value Of Equity 10.44b)
Interest Expense / Debt = 0.91% (Interest Expense 76.2m / Debt 8.37b)
Taxrate = 17.09% (439.3m / 2.57b)
NOPAT = 2.49b (EBIT 3.00b * (1 - 17.09%))
Current Ratio = 1.44 (Total Current Assets 7.08b / Total Current Liabilities 4.91b)
Debt / Equity = 0.90 (Debt 8.37b / last Quarter total Stockholder Equity 9.32b)
Debt / EBITDA = 2.12 (Net Debt 7.05b / EBITDA 3.95b)
Debt / FCF = 5.32 (Debt 8.37b / FCF TTM 1.57b)
Total Stockholder Equity = 8.90b (last 4 quarters mean)
RoA = 9.00% (Net Income 2.14b, Total Assets 23.74b )
RoE = 23.99% (Net Income TTM 2.14b / Total Stockholder Equity 8.90b)
RoCE = 18.29% (Ebit 3.00b / (Equity 8.90b + L.T.Debt 7.52b))
RoIC = 14.98% (NOPAT 2.49b / Invested Capital 16.63b)
WACC = 8.60% (E(75.39b)/V(83.76b) * Re(9.47%)) + (D(8.37b)/V(83.76b) * Rd(0.91%) * (1-Tc(0.17)))
Shares Correlation 3-Years: -100.0 | Cagr: -0.30%
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 75.13% ; FCFE base≈1.77b ; Y1≈1.99b ; Y5≈2.67b
Fair Price DCF = 126.9 (DCF Value 35.98b / Shares Outstanding 283.6m; 5y FCF grow 14.34% → 3.0% )
EPS Correlation: -12.83 | EPS CAGR: -55.65% | SUE: -5.0 | # QB: 0
Revenue Correlation: 53.45 | Revenue CAGR: 3.75% | SUE: -0.31 | # QB: 0

Additional Sources for ECL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle